Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
A historic first for a devastating rare disease. The FDA has approved Zanvastro (zilganersen), marking the first-ever treatment for Alexander disease — a rare, progressive neurological disorder affecting fewer than 1 in a million people. The drug works by reducing the buildup of abnormal GFAP protein in the brain and showed significantly improved walking speed and motor function in clinical trials.
A historic first for a devastating rare disease
The FDA has approved Zanvastro (zilganersen), developed by Ionis, as the first-ever treatment for Alexander disease — a rare, progressive neurological disorder caused by mutations in the gene that produces glial fibrillary acidic protein (GFAP). Until now, patients had only supportive care as the disease relentlessly progressed, causing seizures, muscle weakness, loss of developmental milestones, and difficulty walking.
Zanvastro is an antisense oligonucleotide that targets the problem at its source — reducing production of the abnormal GFAP protein before it can accumulate and damage the nervous system. It's administered via intrathecal injection (into the spinal canal) every three months by a trained healthcare professional, and is approved for both pediatric and adult patients, including infants under 2 years.
Key Takeaways
Why it matters: Alexander disease affects fewer than 1 in a million people, leaving patients and families with virtually no options. This approval is a landmark moment — not just for this community, but as a proof of concept that antisense oligonucleotide therapies can tackle ultra-rare neurological diseases driven by protein accumulation.
